Pan-Asian adapted ESMO Clinical Practice Guidelines for the Diagnosis Treatment and Follow-up of Patients with Renal Cell Carcinoma
Published 01 DEC 2021 – ESMO OPEN (2021)
Authors: R. Kanesvaran1, C. Porta, A. Wong, T. Powles, Q. S. Ng, M. Schmidinger, D. Ye, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y.-S. Pu, C.-C. Yen, M. Saad, H. J. Lee, H. Kitamura, G. S. Bhattacharyya1, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino & G. Pentheroudakis
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of renal cell carcinoma was published in 2019 with an update planned for 2021. It was therefore decided by both the ESMO and the Singapore Society of Oncology (SSO) to convene a special, virtual guidelines meeting in May 2021 to adapt the ESMO 2019 guidelines to take into account the ethnic differences associated with the treatment of renal cell carcinomas in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with renal cell carcinoma representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate.